Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMGRAFT: Allo-SCT for Graft Failure
NCT00048399Phase 2Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Dec 2000
- Primary completion
- Oct 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in Graft failure, sponsored by Baylor College of Medicine. Primary endpoints: Safety at 1 year, Feasibility at 1 year and 1 more. Started Dec 2000; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
Graft failure
Beyond the preview
Go deeper on NCT00048399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048399.